These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18177942)

  • 1. Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action.
    Casini A; Hartinger C; Gabbiani C; Mini E; Dyson PJ; Keppler BK; Messori L
    J Inorg Biochem; 2008 Mar; 102(3):564-75. PubMed ID: 18177942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.
    Casini A; Guerri A; Gabbiani C; Messori L
    J Inorg Biochem; 2008; 102(5-6):995-1006. PubMed ID: 18289690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies.
    Nobili S; Mini E; Landini I; Gabbiani C; Casini A; Messori L
    Med Res Rev; 2010 May; 30(3):550-80. PubMed ID: 19634148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead.
    Wang Y; He QY; Sun RW; Che CM; Chiu JF
    Eur J Pharmacol; 2007 Jan; 554(2-3):113-22. PubMed ID: 17116302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis.
    Pratesi A; Gabbiani C; Ginanneschi M; Messori L
    Chem Commun (Camb); 2010 Oct; 46(37):7001-3. PubMed ID: 20730210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copper, gold and silver compounds as potential new anti-tumor metallodrugs.
    Tan SJ; Yan YK; Lee PP; Lim KH
    Future Med Chem; 2010 Oct; 2(10):1591-608. PubMed ID: 21426151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c.
    Casini A; Gabbiani C; Mastrobuoni G; Pellicani RZ; Intini FP; Arnesano F; Natile G; Moneti G; Francese S; Messori L
    Biochemistry; 2007 Oct; 46(43):12220-30. PubMed ID: 17924668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gold(III) compounds of 1,4,7-triazacyclononane showing high cytotoxicity against A-549 and HCT-116 tumor cell lines.
    Shi P; Jiang Q; Lin J; Zhao Y; Lin L; Guo Z
    J Inorg Biochem; 2006 May; 100(5-6):939-45. PubMed ID: 16472862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin.
    Calamai P; Carotti S; Guerri A; Mazzei T; Messori L; Mini E; Orioli P; Speroni GP
    Anticancer Drug Des; 1998 Jan; 13(1):67-80. PubMed ID: 9474243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties.
    Gabbiani C; Casini A; Messori L; Guerri A; Cinellu MA; Minghetti G; Corsini M; Rosani C; Zanello P; Arca M
    Inorg Chem; 2008 Apr; 47(7):2368-79. PubMed ID: 18314951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gold(III) complexes as a new family of cytotoxic and antitumor agents.
    Marcon G; Messori L; Orioli P
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):337-46. PubMed ID: 12113057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
    Casini A; Gabbiani C; Sorrentino F; Rigobello MP; Bindoli A; Geldbach TJ; Marrone A; Re N; Hartinger CG; Dyson PJ; Messori L
    J Med Chem; 2008 Nov; 51(21):6773-81. PubMed ID: 18834187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synthesis, chemical and biological properties of dichlorido(azpy)gold(III) chloride (azpy=2-(phenylazo)pyridine) and the gold-induced conversion of the azpy ligand to the chloride of the novel tricyclic pyrido[2,1-c][1,2,4]benzotriazin-11-ium cation.
    Garza-Ortiz A; den Dulk H; Brouwer J; Kooijman H; Spek AL; Reedijk J
    J Inorg Biochem; 2007 Nov; 101(11-12):1922-30. PubMed ID: 17637477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicinal Chemistry of Gold Anticancer Metallodrugs.
    Casini A; Sun RW; Ott I
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A gold(III) porphyrin complex with antitumor properties targets the Wnt/beta-catenin pathway.
    Chow KH; Sun RW; Lam JB; Li CK; Xu A; Ma DL; Abagyan R; Wang Y; Che CM
    Cancer Res; 2010 Jan; 70(1):329-37. PubMed ID: 19996284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability.
    Gabbiani C; Casini A; Kelter G; Cocco F; Cinellu MA; Fiebig HH; Messori L
    Metallomics; 2011 Dec; 3(12):1318-23. PubMed ID: 21887452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein targets for anticancer gold compounds: mechanistic inferences.
    Gabbiani C; Messori L
    Anticancer Agents Med Chem; 2011 Dec; 11(10):929-39. PubMed ID: 21864237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclometalated Complexes of Platinum and Gold with Biological Properties: State-of-the-Art and Future Perspectives.
    Jurgens S; Kuhn FE; Casini A
    Curr Med Chem; 2018 Feb; 25(4):437-461. PubMed ID: 28554319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical fluoroquinolone gold(III) chelates as potential anticancer agents: relevance of DNA and protein interactions for their mechanism of action.
    Gouvea LR; Garcia LS; Lachter DR; Nunes PR; de Castro Pereira F; Silveira-Lacerda EP; Louro SR; Barbeira PJ; Teixeira LR
    Eur J Med Chem; 2012 Sep; 55():67-73. PubMed ID: 22835721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: solution behavior, reactions with model proteins, antiproliferative properties.
    Maiore L; Cinellu MA; Nobili S; Landini I; Mini E; Gabbiani C; Messori L
    J Inorg Biochem; 2012 Mar; 108():123-7. PubMed ID: 22173093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.